6 - 10 of 69
01.07.2010
BB BIOTECH VENTURES: Successful exit from largest portfolio investment
Sanofi‐aventis has signed a definitive agreement to acquire TargeGen, Inc., a private company in the portfolio of BB BIOTECH VENTURES II since 2005. The transaction volume amounts to a maximum of USD 560 mn. TargeGen was the largest position held in the portfolio. This exit is yet another confirmation of the successful portfolio strategy pursued by Bellevue Asset Management's private equity vehicle.
Sanofi‐aventis has signed a definitive agreement to acquire TargeGen, Inc., a private company in the portfolio of BB BIOTECH VENTURES II since 2005. The transaction volume amounts to a maximum of USD 560 mn. TargeGen was the largest position held in the portfolio. This exit is yet another confirmation of the successful portfolio strategy pursued by Bellevue Asset Management's private equity vehicle.
25.06.2010
Cash: Interview with Elena Ogram, BB Silk Road Opps.
Interview of Cash Magazine on the growth in the Frontier Markets with Elena Ogram, Fundmanager BB Silk Road Opportunities.
15.06.2010
Bellevue Asset Management creates independent Healthcare Advisory Board
09.06.2010
Finanz & Wirtschaft's interview with Elena Ogram, Portfolio Manager, Silk Road Opportunities (German only)